• Explore /
  • Poster
  • / LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).

LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).

Abstract Poster

Authors

Rebecca Dent

Rebecca Alexandra Dent

Division of Medical Oncology, National Cancer Centre, Singapore, Singapore

Rebecca Alexandra Dent , Sung-Bae Kim , Seock-Ah Im , Sibel Blau , Antoinette R. Tan , Steven Isakoff , Mafalda Oliveira , Cristina Saura , Matthew Wongchenko , Amy V. Kapp , Wai Y. Chan , Stina M. Singel , Daniel J. Maslyar , Jose Baselga , Marc Espie

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02162719

Citation

J Clin Oncol 35, 2017 (suppl; abstr 1009)

DOI

10.1200/JCO.2017.35.15_suppl.1009

Abstract #

1009

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Mafalda Oliveira

First Author: Bradley Corr

First Author: Maria Cortes

First Author: Sylvia Adams